SpectraCell Blog

Study suggests testosterone therapy in men not harmful to prostate...

Posted by SpectraCell Laboratories, Inc. on Fri, Mar 06, 2015 @ 11:04 AM

 

Recent finding suggests testosterone therapy in men not harmful to prostatetestosterone


In a recently published study, 1023 hypogonadal men who received testosterone therapy were monitored for an average of 5 years for prostate cancer. The authors concluded that “testosterone therapy in hypogonadal men does not increase the risk of prostate cancer” although the authors did explicitly note that there was not control group in this study of men not taking testosterone.

Similar conclusions were reported in a different review of a testosterone replacement therapy in men, although the effect of testosterone on cardiovascular disease and events was much less clear. Whether or not to treat men with testosterone remains equivocal, as highlighted in the clinical decisions case study listed below.
(Journal of Urology, January 2015)
(Therapeutic Advances in Drug Safety, October 2014)
(New England Journal of Medicine, November 2014)

LINK to ABSTRACT Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
LINK to ABSTRACT
Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. LINK to FREE FULL TEXT
LINK to CASE STUDY 
Clinical decisions. Testosterone-replacement therapy.

For more information or to get tested, please visit www.spectracell.com

 

Topics: SpectraCell, micronutrient, Hormones, Testosterone